ALK-Abello A/S Series B | Cash Flow

Fiscal year is January-December. All values DKK Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
61,000.00
181,000.00
344,000.00
270,000.00
158,000.00
170,000
Depreciation, Depletion & Amortization
127,000.00
140,000.00
158,000.00
163,000.00
181,000.00
193,000
Other Funds
5,000.00
-
-
-
-
60,000
Funds from Operations
140,000.00
267,000.00
269,000.00
492,000.00
105,000.00
21,000
Changes in Working Capital
6,000.00
53,000.00
86,000.00
87,000.00
282,000.00
74,000
Net Operating Cash Flow
146,000.00
320,000.00
183,000.00
405,000.00
387,000.00
95,000
Capital Expenditures
253,000.00
202,000.00
199,000.00
225,000.00
267,000.00
Sale of Fixed Assets & Businesses
-
-
47,000.00
21,000.00
3,000.00
Purchase/Sale of Investments
-
7,000.00
-
-
-
Net Investing Cash Flow
231,000.00
219,000.00
165,000.00
204,000.00
358,000.00
Cash Dividends Paid - Total
49,000.00
49,000.00
49,000.00
49,000.00
49,000.00
Issuance/Reduction of Debt, Net
-
2,000.00
320,000.00
130,000.00
17,000.00
Net Financing Cash Flow
74,000.00
124,000.00
298,000.00
39,000.00
620,000.00
Net Change in Cash
165,000.00
23,000.00
319,000.00
232,000.00
129,000.00
Free Cash Flow
40,000.00
154,000.00
30,000.00
226,000.00
627,000.00
Net Assets from Acquisitions
-
24,000.00
12,000.00
-
94,000.00
Other Sources
22,000.00
-
-
-
-
Change in Capital Stock
20,000.00
73,000.00
27,000.00
42,000.00
686,000.00
Exchange Rate Effect
6,000.00
-
3,000.00
8,000.00
4,000.00
Other Uses
-
-
1,000.00
-
-

About ALK-Abello A/S

View Profile
Address
Bøge Allé 6-8
Hørsholm CR 2970
Denmark
Employees -
Website http://www.alk.net
Updated 07/08/2019
ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. It also manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics.